Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Aspen Aerogels Q4 Earnings Call Highlights

View original at finance.yahoo.com
Aspen Aerogels Q4 Earnings Call Highlights Aspen Aerogels logo Aspen Aerogels (NYSE:ASPN) executives said 2025 was a “transitional year,” marked by a resetting electric vehicle (EV) market in North America and an energy industrial business weighted toward maintenance work rather than large project awards…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Goal is scaling energy industrial into a $200 million high-margin segment without incremental capital investment

    80% confidence
  • 2025 was a transitional year marked by a resetting EV market in North America and energy industrial business weighted toward maintenance work

    80% confidence
  • U.S. EV sales dropped significantly in the fourth quarter

    80% confidence
  • LNG market is in a multi-year build cycle and Aspen expects LNG and natural gas infrastructure activity in 2026 to roughly double versus 2025 in both project count and revenue contribution

    80% confidence
  • Aspen is engaged in multiple qualifications and bids for BESS applications and expects to begin generating revenue from this segment in 2026

    80% confidence
  • From the reset level, the company expects EV penetration to resume growth at a more measured pace than in prior years

    80% confidence
  • Aspen expects GM and other North American OEMs to reassess EV demand absent incentives and regulation during the first half of 2026

    80% confidence
  • Aspen now has a robust subsea pipeline and expects strong demand through the decade as projects move into deeper water and tougher environments

    80% confidence
  • Gross margin was materially impacted by lower production volumes and discrete items in Q4

    80% confidence
  • Energy industrial segment was largely absent subsea project activity in 2025 that contributed to record years in 2023 and 2024

    80% confidence
  • Excluding one-time items, gross margin would have been approximately 27% and adjusted EBITDA about $13 million for full year 2025

    80% confidence
  • Battery electric vehicles represent over 20% of new vehicle registrations in Europe

    80% confidence
  • Aspen can rekindle prior momentum in building and construction, particularly in Europe where building styles and thermal efficiency regulation support retrofit applications

    80% confidence
  • It is still early to provide long-term revenue projections for BESS but the company would not pursue the market unless it had impactful growth potential

    80% confidence
  • Fire safety is a key driver for BESS interest

    80% confidence
  • Strategic review is a disciplined evaluation conducted from a position of financial strength and operational progress

    80% confidence
  • Company expects net cash outflows of $10 million to $15 million during Q1 2026 but expects to end Q1 above December cash balance due to GM payment

    80% confidence
  • Aspen is positioned across the entire LNG value chain, not solely liquefaction

    80% confidence
  • GM has maintained its full line of EV nameplates and remains dedicated to long-term EV success

    80% confidence
  • Incremental revenue above breakeven is expected to carry 50% to 60% adjusted EBITDA margins with limited incremental capital investment

    80% confidence
  • The company does not believe Q4 profitability reflects its go-forward cost structure

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com